A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

Semaglutide injections reversed some cases of MASH liver disease in clinical trials, reducing inflammation in 62.9% of ...

Novo Nordisk Canada announced that Health Canada has accepted for review, under the Priority Review policy, its supplemental ...

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly ...

Once-weekly semaglutide 2.4 mg significantly reduced steatohepatitis and liver fibrosis symptoms among adults with metabolic ...

The New England Journal of Medicine (NEJM) published results from part 1 of the ongoing phase 3 ESSENCE trial which ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

Semaglutide is the key component of weight loss and diabetes drugs like Ozempic and Wegovy, and an international team of ...

Researchers chose to investigate semaglutide as a potential treatment because this class of drug has previously been shown to reduce fat and liver scarring for people with MASH. Between 2021 and ...

An international study led by the director of Virginia Commonwealth University’s liver institute suggests that ...

Semaglutide effectively treats liver disease in two thirds of patients, new research has found. Semaglutide effectively treats liver disease in two thirds of patients, new research has found.

A global trial finds Wegovy and Ozempic significantly improve liver health in patients and treats those with advanced fatty ...